Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics

April 10, 2024 06:15 AM PDT | By Cision

Google News:

Development of exosome therapy to treat inflammatory bowel disease by VesiCURE Therapeutics — Image source: Kalkine Media

Recent News

From The Streets Of Redfern To The Stage: Steven Murphy’s Explosive Me...

How To Make Free Ai Animated Videos From Text In 2025 With The Best Ai...

Cuba’s sugar collapse threatens iconic rum industry as output hits his...

Super Micro stock surges after Saudi deal, upbeat rating and AI optimi...

SUZHOU, China, April 10, 2024 /PRNewswire/ -- IBD, or Inflammatory Bowel Disease, traditionally more prevalent in developed nations, is increasingly observed in developing regions like China. It is a chronic, nonspecific inflammatory gastrointestinal disorder with an unknown etiology, characterized by symptoms such as abdominal pain, diarrhea, fever, and bloody stool. However, treatment options remain limited, focusing primarily on managing complications and promoting inflammatory wound healing to enhance patients' quality of life. With its high recurrence rate, there is a pressing need for effective drug development to address the unmet medical needs associated with IBD.

Mesenchymal stem cells (MSCs) are pluripotent stem cells capable of modulating immune cells in their microenvironment through the secretion of growth factors, chemokines, and extracellular vesicles (EVs). Numerous reports highlight the therapeutic potential and clinical efficacy of MSC-EVs in various conditions, including osteoarthritis, pulmonary fibrosis, autoimmune diseases, and organ transplantation. Leveraging the advantages of EVs—such as biocompatibility, low immunogenicity, enhanced safety, efficient drug delivery, and long-term storage—MSC-EVs hold promise for therapeutic applications in IBD.

Recent research by VesiCURE Therapeutics, published in BioRxiv, entitled "Mesenchymal stem cell-derived extracellular vehicles attenuate symptoms in dextran sulfate-induced ulcerative colitis mouse model"(DOI: https://doi.org/10.1101/2024.02.01.578325), demonstrates the effectiveness of MSC-EVs in treating iBD in a mouse model of ulcerative colitis induced by dextran sulfate. The study reveals significant alleviation of symptoms, including weight loss, diarrhea, and occult blood in stools. Furthermore, at the cellular level, MSC-EV administration restores mucosal integrity and reduces immune cell infiltration in the submucosa of iBD model mice. As a pioneer in exosome therapy, VesiCURE is dedicated to advancing EV-based drug development to create accessible and efficient therapeutic solutions for patients worldwide.

Media Contact: [email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.